AbCellera Biologics 2025 Q3 Earnings Revenue Up 37.6% Despite 11.8% Wider Net Loss

AbCellera Biologics (ABCL) reported fiscal 2025 Q3 earnings on November 6, 2025, with revenue rising 37.6% year-over-year but a net loss widening by 11.8%. The company’s guidance aligns with its focus on advancing two lead programs through Phase 1 trials and leveraging $680 million in liquidity.

Revenue

AbCellera’s total revenue surged to $8.96 million in Q3 2025, up from $6.51 million in Q3 2024, driven by a 40% increase in research fees and a 1302% surge in licensing revenue over nine months. The latter was fueled by new agreements, while research fees expanded due to ongoing discovery projects.

Earnings/Net Income

The company’s net loss widened to $57.12 million in Q3 2025, or $0.19 per share, compared to $51.11 million, or $0.17 per share, in the prior year. The EPS of -$0.19 reflects a 11.8% wider loss compared to the previous year, signaling continued financial strain.

Post-Earnings Price Action Review

The strategy of buying ABCL shares on earnings announcements and holding for 30 days showed mixed results. While a 29.41% short-term gain in Q1 2025 followed a revenue beat, subsequent quarters saw volatility, including an 11.76% decline. Cumulative returns over three years were inconsistent, with a notable 87% year-to-date surge offset by biotech-specific risks like R&D delays and regulatory uncertainties. Investors must weigh these factors against the company’s aggressive clinical-stage bets.

CEO Commentary

CEO Carl Hansen highlighted progress in transitioning to a clinical-stage biotech, with Phase 1 trials for ABCL635 and ABCL575 underway. He emphasized $680 million in liquidity to advance programs and expand partnerships, underscoring confidence in operational momentum.

Guidance

AbCellera plans to prioritize Phase 1 development for its lead programs while leveraging $680 million in liquidity, including $523 million in cash and $159 million in non-dilutive funding. No explicit revenue or EPS guidance was provided, with management focusing on operational milestones.

Additional News

AbCellera appointed Dr. Sarah Nunberg as Chief Medical Officer, bringing 20+ years of clinical drug development experience. The company also advanced 103 partner-initiated programs cumulatively and expanded its clinical pipeline, with 18 molecules in trials. Additionally, construction of a small-scale manufacturing facility is on track to enhance antibody development capabilities.